Abstract Treatment protocols for breast cancer depend predominantly on receptor status with
respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and …

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 …

Triple-negative breast cancers (TNBCs) are defined as tumors that are negative for
estrogen, progesterone and HER-2 receptor. At a percentage of 10-20% TNBCs represent a …

Background: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or
Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in …

Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the
expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal …

Purpose: Gene expression analysis identifies several breast cancer subtypes. We examined
the relationship of neoadjuvant chemotherapy response to outcome among these breast …

Breast cancer is the most common malignancy for women. Multiple oncogenes, tumor
suppressor genes, sex steroid hormones and their receptors are involved in the genesis and …

Context Triple-negative breast cancer (TNBC) is a subgroup of breast cancers that by
definition lack expression of estrogen receptor, progesterone receptor, and human …

Triple negative breast cancers (TNBCs) represent 10%–20% of primary breast cancers, and
despite having greater initial sensitivity to cytotoxic chemotherapy, patients with TNBCs have …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …